Syndax Pharmaceuticals: A Tale Of Two Drug Launches

Group 1 - The article expresses a beneficial long position in the shares of SNDX, indicating a positive outlook on the company's stock performance [1] - The author emphasizes that the opinions presented are personal and not influenced by any business relationships with the companies mentioned [1] - The article does not provide personalized investment advice, urging readers to conduct their own due diligence before making investment decisions [2][3] Group 2 - The commentary highlights that past performance is not indicative of future results, which is a common disclaimer in investment analysis [3] - It is noted that the views expressed may not reflect those of the platform as a whole, indicating a diversity of opinions among analysts [3] - The article clarifies that the analysts involved may not be licensed or certified, which is important for readers to consider when interpreting the analysis [3]